Earliest Stage Treatment of Aktinic Keratosis With Imiquimod 3.75% Cream

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

Earliest Stage Treatment of Actinic Keratosis with Imiquimod 3.75% Cream:

The study is to demonstrate that Aktinic Keratosis are present before they are clinically visible, i.e. in a subclinical stage. Since on the basis of the research situation, also subclinical AK can proliferate into the dermis, it is possible that with the application of Imiquimod on chronically light-exposed skin, undetected squamous cell carcinoma can be recognized and treated at the same time.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Medical University of Graz
• Treatments: Imiquimod

Criteria

Inclusion

• Male and female supposed-healthy volunteer outpatients, age: > 50 years.

• Diagnosis: patients with chronically UV-exposed photodamaged facial skin.

• Consent by signing the ICF (Informed Consent Form)

Exclusion

• Current participation in another clinical trial

• Patients who are using topical glucocorticoids on the face.

• Known intolerance/hypersensitivity to imiquimod

• Pregnant/breastfeeding women

• Systemic disease, immunodeficiency